Earlier this year, South Korea’s Ministry of Science, ICT and Future Planning published the “Survey of Research and Development in Korea, 2013,” presenting its latest review of South Korean R&D expenditures. The country’s R&D spending is particularly notable as South Korea, at 4.15%, has the highest R&D expenditures as a percentage of GDP among Organization […]
Pharmaceutical companies in China have increased their investment in R&D to 6.9% of revenue in 2014 from 3.9% in 2009. This has helped them make the shift from manufacturers of active pharmaceutical ingredients to drug developers. Sino Biopharm, for example, stepped up its R&D investment sevenfold to $140 million from 2009 to 2014. This, along […]
The Chinese government is spending over $200 billion annually on R&D, or about 2% of GDP. But, in many ways, the funding is applied ineffectively. For example, while government incentives have prompted patent filings, when controlling for quality, patent numbers fall short of many other countries’. According to the World Bank, state-owned enterprises have shown […]
This month, India’s Cabinet Committee on Economic Affairs approved an INR 1,750 crore ($272 million) proposal to strengthen and upgrade the central and state drug regulatory systems over a three-year period. The central structures, which include the Central Drug Standards Organization (CDSCO), will receive INR 900 crore, and the state governments, after signing a memorandum […]
Calendar year second quarter organic growth continued at a strong pace for major US publicly held instrument and laboratory product companies. However, currency headwinds, as well as weakness in industrial markets and Japan expunged organic growth. Currency reduced gains by about 7%, resulting in roughly flat second quarter average sales growth. Pharmaceutical and biotechnology markets […]
R&D is on the rise in China, as the country attracted $5.5 billion in 88 foreign greenfield R&D projects from 2010 to 2014, according to fDi Markets. This places China at the top globally in amount invested in such projects, and second in number of projects to the US, which had 91. The pharmaceuticals, business […]
The steel industry is experiencing globalization, with causes including excess production capacity, the highest of which is in China. Worldwide growth in steel demand slowed to 0.6% in 2014, with 0.5% growth in demand predicted by the World Steel Association in 2015. Correspondingly, in 2014, global steel production experienced a slowdown in growth to 1.2%. […]
With the first half of the year behind us, let us reflect on the state of the analytical and life science instrumentation and lab products market, how it has developed thus far and what is in store for the rest of 2015. The original January forecast (see IBO 1/15/15) was published without the benefit of […]
This month, the South Korean government approved the “2016 Government R&D Project Budget Allocation and Arrangement.” The government plans to spend $11.2 billion on R&D projects next year, a reduction of 2.3%. The budget bill applies to 373 projects run by 19 departments. Despite the overall drop in R&D funding, the budget for small and […]
In the US, Europe, Australia and Canada, 2014 biotech sales totaled $123.1 billion, rising 24.3%, with each country or region accounting for 76%, 19%, 5% and 0.2% of sales, respectively. Sales of Gilead Science’s hepatitis C drugs accounted for a sizable portion of revenues in 2014; adjusting for Gilead, growth for the industry was 12%. […]
Pay Invoice
Latest Blogs
-
Lab Instrument Sales in China Collapse
March 29, 2024 1:15 pm
-
Pittcon 2024 Comes to San Diego
February 14, 2024 1:10 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
